Scientific article
Open access

Risk Stratification in Pulmonary Arterial Hypertension, Update and Perspectives

Published inJournal of clinical medicine, vol. 12, no. 13, 4349
First online date2023-06-28

Risk stratification in pulmonary arterial hypertension (PAH) is crucial in assessing patient prognosis. It serves a prominent role in everyday patient care and can be determined using several validated risk assessment scores worldwide. The recently published 2022 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines underline the importance of risk stratification not only at baseline but also during follow-up. Achieving a low-risk status has now become the therapeutic goal, emphasising the importance of personalised therapy. The application of these guidelines is also important in determining the timing for lung transplantation referral. In this review, we summarise the most relevant prognostic factors of PAH as well as the parameters used in PAH risk scores and their evolution in the guidelines over the last decade. Finally, we describe the central role that risk stratification plays in the current guidelines not only in European countries but also in Asian countries.

  • PAH prognosis
  • Lung transplantation
  • Pulmonary arterial hypertension
  • Risk stratification
Citation (ISO format)
VRAKA, Argyro et al. Risk Stratification in Pulmonary Arterial Hypertension, Update and Perspectives. In: Journal of clinical medicine, 2023, vol. 12, n° 13, p. 4349. doi: 10.3390/jcm12134349
Main files (1)
Article (Published version)
ISSN of the journal2077-0383

Technical informations

Creation10/20/2023 12:59:38 PM
First validation11/14/2023 8:14:49 AM
Update time11/14/2023 8:14:49 AM
Status update11/14/2023 8:14:49 AM
Last indexation05/06/2024 5:20:21 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack